Tetra Bio-Pharma   Report issue

For profit Phase 4
Founded: Longueuil QC Canada (2007)

Organization Overview

First Clinical Trial
2017
NCT04314804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Tetra Bio-Pharma

Active Ingredients

Drugs in Phase 4 Trials (2)

cannabidiol (Epidiolex) (7 trials)

tetrahydrocannabinol (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Cachexia (Phase 3)

Cancer Pain (Phase 2)

Chronic Pain (Phase 4)

Marijuana Abuse (Phase 2)

Neoplasms (Phase 3)

Wasting Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 2